Sanofi: UBS raises target price

(CercleFinance.com) - While maintaining its "neutral" rating on Sanofi shares, UBS has raised its target price for them from E93 to E100, with the latter roughly in line with the French pharmaceutical group's current share price.


"We think Dupixent can reach over EUR20bn in sales. However, re-rating potential may be limited without more clarity on replacement power," the broker summarises.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.